• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与 2 型家族性部分脂肪营养不良相关的临床谱:系统评价。

Clinical Spectrum of -Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review.

机构信息

UETeM-Molecular Pathology Group, Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, IDIS-CIMUS, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain.

Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain.

出版信息

Cells. 2023 Feb 24;12(5):725. doi: 10.3390/cells12050725.

DOI:10.3390/cells12050725
PMID:36899861
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10000975/
Abstract

Type 2 familial partial lipodystrophy (FPLD2) is a laminopathic lipodystrophy due to pathogenic variants in the gene. Its rarity implies that it is not well-known. The aim of this review was to explore the published data regarding the clinical characterisation of this syndrome in order to better describe FPLD2. For this purpose, a systematic review through a search on PubMed until December 2022 was conducted and the references of the retrieved articles were also screened. A total of 113 articles were included. FPLD2 is characterised by the loss of fat starting around puberty in women, affecting limbs and trunk, and its accumulation in the face, neck and abdominal viscera. This adipose tissue dysfunction conditions the development of metabolic complications associated with insulin resistance, such as diabetes, dyslipidaemia, fatty liver disease, cardiovascular disease, and reproductive disorders. However, a great degree of phenotypical variability has been described. Therapeutic approaches are directed towards the associated comorbidities, and recent treatment modalities have been explored. A comprehensive comparison between FPLD2 and other FPLD subtypes can also be found in the present review. This review aimed to contribute towards augmenting knowledge of the natural history of FPLD2 by bringing together the main clinical research in this field.

摘要

2 型家族性部分脂肪营养不良(FPLD2)是一种层粘连蛋白病性脂肪营养不良,由 基因的致病性变异引起。由于其罕见性,人们对它的了解并不多。本综述的目的是探讨已发表的关于该综合征临床特征的资料,以便更好地描述 FPLD2。为此,我们进行了一次系统的文献检索,检索了 PubMed 上截至 2022 年 12 月的资料,并对检索到的文章的参考文献进行了筛选。共纳入了 113 篇文章。FPLD2 的特征是女性青春期前后开始失去脂肪,影响四肢和躯干,脂肪在面部、颈部和腹部内脏堆积。这种脂肪组织功能障碍导致与胰岛素抵抗相关的代谢并发症的发展,如糖尿病、血脂异常、脂肪肝疾病、心血管疾病和生殖障碍。然而,已经描述了很大程度的表型变异性。治疗方法针对相关的合并症,并且已经探索了最近的治疗方式。本综述还对 FPLD2 与其他 FPLD 亚型进行了全面比较。本综述旨在通过汇集该领域的主要临床研究,为增加对 FPLD2 自然史的认识做出贡献。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea1/10000975/ff3119d1c8c0/cells-12-00725-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea1/10000975/e026e3ed6875/cells-12-00725-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea1/10000975/149156c19384/cells-12-00725-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea1/10000975/fbabcc9dbb0a/cells-12-00725-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea1/10000975/ff3119d1c8c0/cells-12-00725-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea1/10000975/e026e3ed6875/cells-12-00725-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea1/10000975/149156c19384/cells-12-00725-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea1/10000975/fbabcc9dbb0a/cells-12-00725-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea1/10000975/ff3119d1c8c0/cells-12-00725-g004.jpg

相似文献

1
Clinical Spectrum of -Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review.与 2 型家族性部分脂肪营养不良相关的临床谱:系统评价。
Cells. 2023 Feb 24;12(5):725. doi: 10.3390/cells12050725.
2
Health professionals' experience of teamwork education in acute hospital settings: a systematic review of qualitative literature.医疗专业人员在急症医院环境中团队合作教育的经验:对定性文献的系统综述
JBI Database System Rev Implement Rep. 2016 Apr;14(4):96-137. doi: 10.11124/JBISRIR-2016-1843.
3
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
4
The measurement and monitoring of surgical adverse events.手术不良事件的测量与监测
Health Technol Assess. 2001;5(22):1-194. doi: 10.3310/hta5220.
5
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.戈谢病酶替代疗法的临床疗效和成本效益:一项系统评价。
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240.
6
Beckwith-Wiedemann Syndrome贝克威思-维德曼综合征
7
Active body surface warming systems for preventing complications caused by inadvertent perioperative hypothermia in adults.用于预防成人围手术期意外低温引起并发症的主动体表升温系统。
Cochrane Database Syst Rev. 2016 Apr 21;4(4):CD009016. doi: 10.1002/14651858.CD009016.pub2.
8
Single-incision sling operations for urinary incontinence in women.女性尿失禁的单切口吊带手术
Cochrane Database Syst Rev. 2017 Jul 26;7(7):CD008709. doi: 10.1002/14651858.CD008709.pub3.
9
Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.生长激素轴治疗与 HIV 相关的脂肪代谢障碍:安慰剂对照试验的系统评价。
HIV Med. 2011 Sep;12(8):453-62. doi: 10.1111/j.1468-1293.2010.00906.x. Epub 2011 Jan 25.
10
Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis.成人伴或不伴有广场恐惧症的惊恐障碍的心理治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2016 Apr 13;4(4):CD011004. doi: 10.1002/14651858.CD011004.pub2.

引用本文的文献

1
Potential Impact of Parental Origin of Inheritance on the Clinical Presentation of Familial Partial Lipodystrophy Type 2 Syndrome.遗传亲本来源对2型家族性部分脂肪营养不良综合征临床表现的潜在影响。
Clin Endocrinol (Oxf). 2025 Oct;103(4):504-512. doi: 10.1111/cen.15303. Epub 2025 Jul 16.
2
Liraglutide use in pediatric type 2 familial partial lipodystrophy caused by LMNA mutation: a case report.利拉鲁肽用于治疗由LMNA突变引起的小儿2型家族性部分脂肪营养不良:一例报告
BMC Pediatr. 2025 Jul 7;25(1):537. doi: 10.1186/s12887-025-05886-0.
3
Brazilian expert consensus on the diagnosis, classification, screening for complications and treatment of familial partial lipodystrophy.

本文引用的文献

1
Identifying congenital generalized lipodystrophy using deep learning-DEEPLIPO.利用深度学习技术 DEEPLIPO 对先天性全身性脂肪营养不良进行识别。
Sci Rep. 2023 Feb 7;13(1):2176. doi: 10.1038/s41598-023-27987-5.
2
Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study.评估volanesorsen治疗家族性部分脂肪营养不良患者代谢并发症的疗效和安全性:BROADEN研究结果:volanesorsen治疗家族性部分脂肪营养不良;BROADEN研究
J Clin Lipidol. 2022 Nov-Dec;16(6):833-849. doi: 10.1016/j.jacl.2022.08.008. Epub 2022 Sep 22.
3
巴西关于家族性部分脂肪营养不良的诊断、分类、并发症筛查及治疗的专家共识。
Diabetol Metab Syndr. 2025 Jun 2;17(1):186. doi: 10.1186/s13098-025-01733-5.
4
Comprehensive impact of mutations in familial partial lipodystrophy type 3: Diagnosis, therapeutic strategies.3型家族性部分脂肪营养不良中突变的综合影响:诊断、治疗策略
World J Diabetes. 2025 Apr 15;16(4):103675. doi: 10.4239/wjd.v16.i4.103675.
5
A case of familial partial lipodystrophy type 2 masquerading as Cushing syndrome: Explaining an atypical phenotype by whole-exome sequencing.一例伪装成库欣综合征的2型家族性部分脂肪营养不良:通过全外显子组测序解释非典型表型
Arch Endocrinol Metab. 2025 Mar 24;69(1):e240293. doi: 10.20945/2359-4292-2024-0293.
6
Safety and effectiveness in an uncontrolled setting of glucagon-like-peptide-1 receptor agonists in patients with familial partial lipodystrophy: Real-life experience from a national reference network.胰高血糖素样肽-1受体激动剂在家族性部分脂肪营养不良患者非对照环境中的安全性和有效性:来自国家参考网络的真实生活经验。
Diabetes Obes Metab. 2025 Apr;27(4):1815-1825. doi: 10.1111/dom.16175. Epub 2025 Jan 20.
7
Case Report: Concurrent pathogenic variants in the gene as a cause of sporadic partial lipodystrophy.病例报告:该基因中的并发致病变体作为散发性部分脂肪营养不良的一个病因。
Front Genet. 2024 Nov 28;15:1468878. doi: 10.3389/fgene.2024.1468878. eCollection 2024.
8
Identification and characterization of a case of mild familial partial lipodystrophy in a carrier of a LMNA p.Arg582Leu variant.一名携带LMNA基因p.Arg582Leu变异的轻度家族性部分脂肪营养不良病例的鉴定与特征分析。
Acta Diabetol. 2025 Feb;62(2):285-288. doi: 10.1007/s00592-024-02396-w. Epub 2024 Oct 29.
9
Familial partial lipodystrophy resulting from loss-of-function PPARγ pathogenic variants: phenotypic, clinical, and genetic features.家族性部分脂肪营养不良源于 PPARγ 功能丧失致病性变异:表型、临床和遗传特征。
Front Endocrinol (Lausanne). 2024 Sep 27;15:1394102. doi: 10.3389/fendo.2024.1394102. eCollection 2024.
10
Genetic and Pathophysiological Basis of Cardiac and Skeletal Muscle Laminopathies.心脏和骨骼肌层状结构病的遗传和病理生理学基础。
Genes (Basel). 2024 Aug 20;15(8):1095. doi: 10.3390/genes15081095.
Lipoatrophic diabetes in familial partial lipodystrophy type 2: From insulin resistance to diabetes.
家族性部分脂肪营养不良2型中的脂肪萎缩性糖尿病:从胰岛素抵抗到糖尿病。
Diabetes Metab. 2023 Mar;49(2):101409. doi: 10.1016/j.diabet.2022.101409. Epub 2022 Nov 15.
4
Phenotypic Differences Among Familial Partial Lipodystrophy Due to or Variants.由……或变体导致的家族性部分脂肪营养不良的表型差异。
J Endocr Soc. 2022 Oct 11;6(12):bvac155. doi: 10.1210/jendso/bvac155. eCollection 2022 Oct 26.
5
Describing the natural history of clinical, biochemical and radiological outcomes of children with familial partial lipodystrophy type 2 (FPLD2) from the United Kingdom: A retrospective case series.描述英国家族性部分脂肪营养不良 2 型(FPLD2)患儿的临床、生化和放射学结局的自然史:一项回顾性病例系列研究。
Clin Endocrinol (Oxf). 2022 Dec;97(6):755-762. doi: 10.1111/cen.14806. Epub 2022 Aug 17.
6
HOTAIR interacts with PRC2 complex regulating the regional preadipocyte transcriptome and human fat distribution.HOTAIR 通过与 PRC2 复合物相互作用调节区域性前脂肪细胞转录组和人类脂肪分布。
Cell Rep. 2022 Jul 26;40(4):111136. doi: 10.1016/j.celrep.2022.111136.
7
Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.脂代谢障碍综合征患者 metreleptin 的治疗适应证和代谢作用:来自国家参考网络的真实临床经验。
Diabetes Obes Metab. 2022 Aug;24(8):1565-1577. doi: 10.1111/dom.14726. Epub 2022 May 12.
8
Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study.用 vupanorsen 选择性靶向血管生成素样蛋白 3(ANGPTL3)治疗家族性部分脂肪营养不良(FPLD)患者:概念验证研究的结果。
Lipids Health Dis. 2021 Dec 5;20(1):174. doi: 10.1186/s12944-021-01589-4.
9
Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy.内源性瘦素浓度不能准确预测部分脂肪营养不良患者 metreleptin 的反应。
J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1739-e1751. doi: 10.1210/clinem/dgab760.
10
Impaired Muscle Mitochondrial Function in Familial Partial Lipodystrophy.家族性部分脂肪营养不良患者的肌肉线粒体功能受损。
J Clin Endocrinol Metab. 2022 Jan 18;107(2):346-362. doi: 10.1210/clinem/dgab725.